We'll see. I just hope that Anavex makes biotech journalists like Adam Feuerstein work hard to find an angle to attack the data this time. We all know it's coming but in the past the data has had too many potential openings for criticism. Hoping this will be the nail in the coffin.
How?...Around 6% will be improving. You can't even take the 2 of 32 people in the P2a trial and compare it to 509, because no one was on a placebo in the P2a. You have to take that percentage and use it compared to those not on a placebo in the P2b. 338 people not on a plaebo...
That means 21 people "may" see a benefit. That is only true if the 2 people that had an effect were diagnosed properly.
News 
Market Data 
Discover 
